Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Organ preconditioning. Arch Surg 2001 Nov;136(11):1263-6

Date

12/26/2001

Pubmed ID

11695970

DOI

10.1001/archsurg.136.11.1263

Scopus ID

2-s2.0-0034763056   38 Citations

Abstract

The initial discovery of cardiac preconditioning has evolved into an exciting series of practical surgical applications. An enormous amount of evidence demonstrating both the safety and efficacy of ischemic preconditioning is available from animal studies. The challenging premise of intentionally subjecting patients and their organs to transient ischemia has acted as a formidable psychological and ethical impediment to the widespread clinical application of organ preconditioning. A more palatable alternative to ischemic preconditioning now involves approved medications designed to manipulate the cellular machinery mediating ischemic preconditioning. Pharmacologically induced preconditioning seems to confer equal organ protection. The relatively brief (but surgically relevant) window of protection provided by strategies such as ischemic preconditioning or adenosine agonists and potassium-adenosine triphosphate channel openers may, in the future, be extended. We have developed and reported the feasibility of liposomal delivery of heat shock protein to cardiac myocytes with subsequent protection against sepsis-induced dysfunction. Targeted strategies will ultimately broaden the therapeutic potential of organ preconditioning.

Author List

Raeburn CD, Cleveland JC Jr, Zimmerman MA, Harken AH

Author

Michael A. Zimmerman MD, FACS Professor in the Surgery department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Animals
Humans
Ischemic Preconditioning
Ischemic Preconditioning, Myocardial
Organ Transplantation
Reconstructive Surgical Procedures
Vascular Surgical Procedures
jenkins-FCD Prod-486 e3098984f26de787f5ecab75090d0a28e7f4f7c0